<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04128995</url>
  </required_header>
  <id_info>
    <org_study_id>R01DK119450</org_study_id>
    <nct_id>NCT04128995</nct_id>
  </id_info>
  <brief_title>Surgical or Medical Treatment</brief_title>
  <acronym>ST2OMP</acronym>
  <official_title>Surgical or Medical Treatment for Pediatric Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital Colorado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that metabolic bariatric surgery will be more effective
      at providing durable glycemic control and reduce co-morbidities than intensive medical
      therapy in youth with type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Youth-onset type 2 diabetes (T2D) leads to early dependence on exogenous insulin and
      progression of T2D co-morbidities, including dyslipidemia, hypertension, non-alcoholic fatty
      liver disease and diabetic kidney disease. The pathophysiology of T2D in youth differs
      considerably from adults and current treatment approaches are in-adequate for youth. Thus,
      exploration of innovative approaches to reduce co-morbidities is critical. Metabolic
      bariatric surgery (MBS) significantly improves multiple outcomes in adults with T2D. Initial
      small, uncontrolled studies of Roux-en-Y gastric bypass also suggest beneficial effects in
      youth with T2D, but definitive studies and understanding of mechanisms in youth-onset T2D are
      lacking, especially with the now more common form of MBS, vertical sleeve gastrectomy (VSG).

      We will test the hypothesis that VSG will be more effective in reducing glycemia and
      comorbidities than the best currently available medical treatment: advanced medical therapy
      (AMT), via pancreatic, enterohepatic and/or metabolic changes. To test this hypothesis, 90
      adolescents with T2D will be studied to compare the effects of VSG vs. AMT on glycemic
      control and T2D-associated comorbidities, as well as underlying mechanisms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 5, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open label prospective clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic Control</measure>
    <time_frame>At one year</time_frame>
    <description>Hemoglobin A1c of &lt;6.5%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic Control</measure>
    <time_frame>At two years</time_frame>
    <description>Hemoglobin A1c &lt;6.5% at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic Variability</measure>
    <time_frame>At one year</time_frame>
    <description>Time In Range by Continuous Glucose Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta Cell Function</measure>
    <time_frame>at 1 and 2 years</time_frame>
    <description>Oral disposition index= Insulin secretion [insulinogenic index] * insulin sensitivity [1/fasting insulin]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha cell function</measure>
    <time_frame>at 1 and 2 years</time_frame>
    <description>Glucagon area under the curve from mixed meal tolerance testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incretin Response</measure>
    <time_frame>at 1 and 2 years</time_frame>
    <description>GLP-1 area under the curve from mixed meal tolerance testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty Liver Disease</measure>
    <time_frame>at 1 and 2 years</time_frame>
    <description>Hepatic Fat (&lt;5% )by Magnetic Resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyslipidemia</measure>
    <time_frame>at 1 and 2 years</time_frame>
    <description>LDL &lt;130mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertension</measure>
    <time_frame>at 1 and 2 years</time_frame>
    <description>Blood pressure &lt;130/80 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic Kidney Disease</measure>
    <time_frame>At 1 and 2 years</time_frame>
    <description>Urinary albumin excretion &lt;30Î¼g/mg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Pediatric Obesity</condition>
  <condition>Bariatric Surgery Candidate</condition>
  <arm_group>
    <arm_group_label>Bariatric Surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric Surgery</intervention_name>
    <description>Vertical Sleeve Gastrectomy and Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin</description>
    <arm_group_label>Bariatric Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advanced Medical Therapy</intervention_name>
    <description>Use of combination medical therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin</description>
    <arm_group_label>Medical Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 13-19.9 years of age at time of consent

          -  Type 2 diabetes by the American Diabetes Association criteria

          -  Negative diabetes-associated antibodies

          -  BMI greater than or equal to 35

          -  Willingness to take oral medications and/or diabetes subcutaneous medications as
             medically indicated

        Exclusion Criteria:

          -  Known type 1 diabetes of maturity onset diabetes on the young (MODY) or secondary
             diabetes

          -  Chronic kidney or liver disease (except NAFLD or DKD)

          -  Pregnancy or breast-feeding

          -  Genetic cause of obesity or hypothalamic obesity

          -  Prior bariatric surgery

          -  History of malignancy

          -  Current participating in another clinical trial affecting study outcomes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy S Shah, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cincinnati Childrens Hospital Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristen J Nadeau, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Colorado</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael A Helmrath, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas H Inge, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Colorado</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy S Shah, MD</last_name>
    <phone>513-636-4744</phone>
    <email>amy.shah@cchmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristen J Nadeau, MD</last_name>
    <phone>(720) 777-6128</phone>
    <email>Kristen.Nadeau@childrenscolorado.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Gross, MS RD</last_name>
      <phone>720-777-6143</phone>
      <email>susan.gross@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Kristen J Nadeau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas H Inge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Megan M Kelsey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsey S Frenck</last_name>
      <phone>513-636-4744</phone>
      <email>kelsey.frenck@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Michael A Helmrath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy S Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stavra Xanthakos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>December 29, 2019</last_update_submitted>
  <last_update_submitted_qc>December 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Medical Center, Cincinnati</investigator_affiliation>
    <investigator_full_name>Amy Shah</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The PI's will also report a of summary results information (including adverse events) after completion of the study. All data from the study including any negative findings will be published in peer reviewed manuscripts.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

